Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Life expectancy in metastatic urothelial bladder cancer patients according to race/ethnicity

F. Chierigo, M. Borghesi, C. Würnschimmel, RS. Flammia, B. Horlemann, G. Sorce, B. Hoeh, Z. Tian, F. Saad, M. Graefen, M. Gallucci, A. Briganti, F. Montorsi, FKH. Chun, SF. Shariat, G. Mantica, N. Suardi, C. Terrone, PI. Karakiewicz

. 2022 ; 54 (7) : 1521-1527. [pub] 20220504

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22017900
E-zdroje Online Plný text

NLK ProQuest Central od 1999-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2011-03-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1999-01-01 do Před 1 rokem

Odkazy

PubMed 35508792
DOI 10.1007/s11255-022-03221-5
Knihovny.cz E-zdroje

PURPOSE: to compare observed overall survival vs age-adjusted lifetable (LT) derived life expectancy (LE) in metastatic urothelial bladder cancer (MBCa) patients according to race/ethnicity. METHODS: We identified Caucasian, African American, Hispanic/Latino and Asian metastatic urothelial bladder cancer patients from 2004 to 2011 within the Surveillance, Epidemiology and End Results database. Social Security Administration tables were used to compute 5 year LE. LT-derived LE was compared to observed overall survival OS. Additionally, we relied on Poisson regression plots to display cancer-specific mortality (CSM) relative to other-cause mortality (OCM) for each race/ethnicity. RESULTS: Overall, 2286 MBCa patients were identified. Of those, 1800 (79%) were Caucasian vs 212 (9.3%) African American vs 189 (8.3%) Hispanic/Latino vs 85 (3.7%) Asians. The median age at diagnosis was 71 years for Asians vs 70 for Caucasians vs 67 for Hispanic/Latinos vs 67 for African Americans. African Americans showed the biggest difference between observed OS and LT-predicted LE at five years (- 83.8%), followed by Hispanic/Latinos (- 81%), Caucasians (- 77%) and Asian patients (- 69%). In Poisson regression plots, Hispanic/Latinos displayed the highest cancer-specific mortality rate (88%), while African/Americans showed the highest other cause mortality rate (12%). Conversely, Asian patients displayed the lowest CSM rate (83%) and second lowest OCM rate (7%). CONCLUSIONS: African Americans showed the least favorable survival profile in MBCa, despite being youngest at diagnosis. Contrarily, Asians displayed the best survival profile in MBCa, despite being oldest at diagnosis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22017900
003      
CZ-PrNML
005      
20220804134443.0
007      
ta
008      
220720s2022 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s11255-022-03221-5 $2 doi
035    __
$a (PubMed)35508792
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Chierigo, Francesco $u Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genoa, Italy. francesco.chierigo@gmail.com $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada. francesco.chierigo@gmail.com $u Department of Urology, Policlinico San Martino Hospital, University of Genova, Largo Rosanna Benzi 10, 16132, Genoa, Italy. francesco.chierigo@gmail.com $1 https://orcid.org/0000000173570758
245    10
$a Life expectancy in metastatic urothelial bladder cancer patients according to race/ethnicity / $c F. Chierigo, M. Borghesi, C. Würnschimmel, RS. Flammia, B. Horlemann, G. Sorce, B. Hoeh, Z. Tian, F. Saad, M. Graefen, M. Gallucci, A. Briganti, F. Montorsi, FKH. Chun, SF. Shariat, G. Mantica, N. Suardi, C. Terrone, PI. Karakiewicz
520    9_
$a PURPOSE: to compare observed overall survival vs age-adjusted lifetable (LT) derived life expectancy (LE) in metastatic urothelial bladder cancer (MBCa) patients according to race/ethnicity. METHODS: We identified Caucasian, African American, Hispanic/Latino and Asian metastatic urothelial bladder cancer patients from 2004 to 2011 within the Surveillance, Epidemiology and End Results database. Social Security Administration tables were used to compute 5 year LE. LT-derived LE was compared to observed overall survival OS. Additionally, we relied on Poisson regression plots to display cancer-specific mortality (CSM) relative to other-cause mortality (OCM) for each race/ethnicity. RESULTS: Overall, 2286 MBCa patients were identified. Of those, 1800 (79%) were Caucasian vs 212 (9.3%) African American vs 189 (8.3%) Hispanic/Latino vs 85 (3.7%) Asians. The median age at diagnosis was 71 years for Asians vs 70 for Caucasians vs 67 for Hispanic/Latinos vs 67 for African Americans. African Americans showed the biggest difference between observed OS and LT-predicted LE at five years (- 83.8%), followed by Hispanic/Latinos (- 81%), Caucasians (- 77%) and Asian patients (- 69%). In Poisson regression plots, Hispanic/Latinos displayed the highest cancer-specific mortality rate (88%), while African/Americans showed the highest other cause mortality rate (12%). Conversely, Asian patients displayed the lowest CSM rate (83%) and second lowest OCM rate (7%). CONCLUSIONS: African Americans showed the least favorable survival profile in MBCa, despite being youngest at diagnosis. Contrarily, Asians displayed the best survival profile in MBCa, despite being oldest at diagnosis.
650    _2
$a černoši nebo Afroameričané $7 D001741
650    12
$a karcinom z přechodných buněk $7 D002295
650    _2
$a etnicita $7 D005006
650    _2
$a lidé $7 D006801
650    _2
$a naděje dožití $7 D008017
650    _2
$a program SEER $7 D018426
650    12
$a nádory močového měchýře $7 D001749
650    _2
$a běloši $7 D044465
655    _2
$a časopisecké články $7 D016428
700    1_
$a Borghesi, Marco $u Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genoa, Italy
700    1_
$a Würnschimmel, Christoph $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Flammia, Rocco Simone $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada $u Department of Maternal-Child and Urological Sciences, Sapienza Rome University, Policlinico Umberto I Hospital, Rome, Italy
700    1_
$a Horlemann, Benedikt $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada
700    1_
$a Sorce, Gabriele $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada $u Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Hoeh, Benedikt $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada $u Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany
700    1_
$a Tian, Zhe $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada
700    1_
$a Saad, Fred $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada
700    1_
$a Graefen, Markus $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Gallucci, Michele $u Department of Maternal-Child and Urological Sciences, Sapienza Rome University, Policlinico Umberto I Hospital, Rome, Italy
700    1_
$a Briganti, Alberto $u Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Montorsi, Francesco $u Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Chun, Felix K H $u Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Departments of Urology, Weill Cornell Medical College, New York, NY, USA $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia $u Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan
700    1_
$a Mantica, Guglielmo $u Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genoa, Italy
700    1_
$a Suardi, Nazareno $u Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genoa, Italy
700    1_
$a Terrone, Carlo $u Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genoa, Italy
700    1_
$a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada
773    0_
$w MED00002396 $t International urology and nephrology $x 1573-2584 $g Roč. 54, č. 7 (2022), s. 1521-1527
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35508792 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134437 $b ABA008
999    __
$a ok $b bmc $g 1821818 $s 1169143
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 54 $c 7 $d 1521-1527 $e 20220504 $i 1573-2584 $m International urology and nephrology $n Int Urol Nephrol $x MED00002396
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace